The Alan Ghitis Association has already funded phase 1 of the project, with great results. Our fundraising campaign continues for phase 2 and the clinical trial.
Prof. Antoni Ribas’s team is making amazing progress! Pfizer is now using the research developed by the team.
In phase one of the project:
We have provided funds to a researcher in his laboratory and they made a fantastic discovery : removing PAK4 protein from cancer cells helps to bring T cells into the tumor to make the patient respond to immunotherapy.
Part of the funds allocated to phase 1 of the project were enabled by a private donation by Bill Ghitis before our association was set up.
The research headed by UCLA’s Dr. Antoni Ribas and the researcher Gabriel Abril-Rodriguez has been focusing on overcoming resistance to immunotherapy.
If you want to know more, click on the links to read some articles published about this project :
In phase two of the project:
Those laboratory-based findings are already being tested in the clinic. The more we understand how PAK4 inhibition works, the easier it is to translate this science into a new drug that helps patients with cancer. The team needs more funds to achieve this!